Sunshine Biopharma (SBFM) Common Equity (2010 - 2026)

Sunshine Biopharma's Common Equity history runs 17 years deep, the most recent figure standing at $21.5 million for Q1 2026.

• Quarterly Common Equity fell 5.22% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 5.22% YoY) and the FY2025 annual result came in at $23.0 million, down 1.97% from the prior year.
• Common Equity was $21.5 million for Q1 2026 at Sunshine Biopharma, down from $23.0 million in the prior quarter.
• Across five years, Common Equity topped out at $41.9 million in Q2 2022 and bottomed at $13.3 million in Q1 2022.
• A 5-year average of $24.5 million and a median of $23.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 10117.97% — and 2023, when it slumped 45.61%.
• Sunshine Biopharma's Common Equity stood at $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then grew by 10.81% to $23.5 million in 2024, then slipped by 1.97% to $23.0 million in 2025, then declined by 6.61% to $21.5 million in 2026.
• Business Quant data shows SBFM's Common Equity at $21.5 million in Q1 2026, $23.0 million in Q4 2025, and $24.2 million in Q3 2025.